NCI-2025-00398

A Randomized Phase III Trial of Chemo-Immunotherapy vs Immunotherapy Alone for the Vulnerable Older Adult with Advanced Non-Small Cell Lung Cancer The ACHIEVE Study

This is a Phase 1a/1b research study testing a new drug, LY4066434, that aims to inhibit KRAS protein activity. KRAS is a protein involved in cell growth and division. Mutations in the KRAS gene are common in many cancers, and these mutations can cause the KRAS protein to become overactive, driving uncontrolled cell growth. A "pan-KRAS inhibitor" aims to block the activity of many different KRAS mutations. The study is enrolling patients with various types of solid tumors, as long as those tumors have a KRAS mutation. The main goals of this trial are to determine a safe and tolerable dose of LY4066434 and to observe how the drug is processed by the body. Researchers will also be looking for any early signs of anti-tumor activity.

Phase 1: First step in testing a new medicine in people, and tests if treatment is safe, determines the right dose, and checks for any side effects.

For more information about the trial, click the link below:

https://clinicaltrials.gov/ct2/show/NCT06607185

Clinical Trial Site: Columbia

To see all available clinical trials click here.